297 related articles for article (PubMed ID: 37208559)
21. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
Zhao SS; Yiu ZZN; Barton A; Bowes J
JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
[TBL] [Abstract][Full Text] [Related]
22. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
Wang R; Zhao J; Li L; Huo Y
J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
[TBL] [Abstract][Full Text] [Related]
23. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
24. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study.
Li X; Meng X; He Y; Spiliopoulou A; Timofeeva M; Wei WQ; Gifford A; Yang T; Varley T; Tzoulaki I; Joshi P; Denny JC; Mckeigue P; Campbell H; Theodoratou E
PLoS Med; 2019 Oct; 16(10):e1002937. PubMed ID: 31626644
[TBL] [Abstract][Full Text] [Related]
25. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Lotta LA; Sharp SJ; Burgess S; Perry JRB; Stewart ID; Willems SM; Luan J; Ardanaz E; Arriola L; Balkau B; Boeing H; Deloukas P; Forouhi NG; Franks PW; Grioni S; Kaaks R; Key TJ; Navarro C; Nilsson PM; Overvad K; Palli D; Panico S; Quirós JR; Riboli E; Rolandsson O; Sacerdote C; Salamanca EC; Slimani N; Spijkerman AM; Tjonneland A; Tumino R; van der A DL; van der Schouw YT; McCarthy MI; Barroso I; O'Rahilly S; Savage DB; Sattar N; Langenberg C; Scott RA; Wareham NJ
JAMA; 2016 Oct; 316(13):1383-1391. PubMed ID: 27701660
[TBL] [Abstract][Full Text] [Related]
26. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
27. Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations.
Ardissino M; Slob EAW; Reddy RK; Morley AP; Schuermans A; Hill P; Williamson C; Honigberg MC; de Marvao A; Ng FS
Eur J Prev Cardiol; 2024 Jun; 31(8):955-965. PubMed ID: 38294056
[TBL] [Abstract][Full Text] [Related]
28. Genetically Determined Chronic Low-Grade Inflammation and Hundreds of Health Outcomes in the UK Biobank and the FinnGen Population: A Phenome-Wide Mendelian Randomization Study.
Si S; Li J; Tewara MA; Xue F
Front Immunol; 2021; 12():720876. PubMed ID: 34386016
[TBL] [Abstract][Full Text] [Related]
29. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
30. Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 × 2 factorial Mendelian randomization analyses.
Li Y; Liu H; Shen C; Li J; Liu F; Huang K; Gu D; Li Y; Lu X
BMC Med; 2024 May; 22(1):201. PubMed ID: 38764043
[TBL] [Abstract][Full Text] [Related]
31. A phenome-wide association study of genetically mimicked statins.
Li S; Schooling CM
BMC Med; 2021 Jun; 19(1):151. PubMed ID: 34187478
[TBL] [Abstract][Full Text] [Related]
32. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
33. Lipid lowering and Alzheimer disease risk: A mendelian randomization study.
Williams DM; Finan C; Schmidt AF; Burgess S; Hingorani AD
Ann Neurol; 2020 Jan; 87(1):30-39. PubMed ID: 31714636
[TBL] [Abstract][Full Text] [Related]
34. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
Miao L; Miao T; Zhang Y; Hao J
BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
[TBL] [Abstract][Full Text] [Related]
35. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
[TBL] [Abstract][Full Text] [Related]
36. Genetic Association of Lipid-Lowering Drugs with Aortic Aneurysms: A Mendelian Randomization Study.
Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
Eur J Prev Cardiol; 2024 Feb; ():. PubMed ID: 38302118
[TBL] [Abstract][Full Text] [Related]
37. Association of lipid-modifying therapy with risk of obstructive sleep apnea: A drug-target mendelian randomization study.
Zou J; Qi S; Sun X; Zhang Y; Wang Y; Li Y; Zhao ZH; Lei D
Toxicol Appl Pharmacol; 2024 Apr; 485():116909. PubMed ID: 38521370
[TBL] [Abstract][Full Text] [Related]
38. Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian Randomization Study.
Bell AS; Rosoff DB; Mavromatis LA; Jung J; Wagner J; Lohoff FW
J Am Heart Assoc; 2022 Nov; 11(21):e026122. PubMed ID: 36285785
[TBL] [Abstract][Full Text] [Related]
39. Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study.
Zhao J; Wang R; Song L; Han H; Wang P; Zhao Y; Zhang Y; Zhang H
Front Endocrinol (Lausanne); 2023; 14():1295412. PubMed ID: 38027179
[TBL] [Abstract][Full Text] [Related]
40. Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.
Zheng C; Lin Y; Jiang B; Zhu X; Lin Q; Luo W; Tang M; Xie L
Front Endocrinol (Lausanne); 2022; 13():954453. PubMed ID: 36299452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
